MS division

[anonymous]

Good place to be? Lots of openings.

 

[anonymous]

Yes. It is a good place to be.

 

[anonymous]

Good place to be? Lots of openings.

Depends. Rebif is a tough sell in this day and age. If Clad gets approved, things could be better, however the expansion seems very extreme considering how niche this drug could possibly be. Would prefer if they left territories alone and just added Clad to our bag. A 33% increase in sales reps for a drug that will likely be used primarily in MS Centers may not make it easy to meet goals. Tons of turnover in the company (upper management and throughout). As with any job, your manager can make your life good, or miserable. Overall, it's been a good company, but the boat has been rocking for several years. And the company seems to be focusing primarily on Oncology, though not sure how well that's working out for them. Rebif still keeps the lights on.

 

[anonymous]

what is rebif's market share these days? is clad getting approved a sure thing?

 

[anonymous]

what is rebif's market share these days? is clad getting approved a sure thing?

Would love to know this answer??

 

[anonymous]

What is bonus target?

 

[anonymous]

Any updates on MS expansion? Anyone have a face to face? Thanks

 

[anonymous]

Any updates on MS expansion? Anyone have a face to face? Thanks

I had a F2F in early July. Final interviews were set for mid August and offers going out early September.

 

[anonymous]

Did people get offers already?

 

[anonymous]

Did people get offers already?

Not sure, but the plan was to extend offers early Sept. with an Oct. 1 start date.

 

[anonymous]

Any offers yet?

 

[anonymous]

Offers started going out this week. Good luck everone

 

[anonymous]

Anyone else heard anything?

 

[anonymous]

I have not heard anything either way. I also reached out to the serono recruiter twice and heard nothing. anyone in the same situation?

 

[anonymous]

Same here.

 

[anonymous]

I hear from my friend (Serono rep) that offers haven’t gone out yet, at least in my area.

 

[anonymous]

Is today the deadline day for offers?

 

[anonymous]

I have heard nothing either way as well.

 

[anonymous]

Depends. Rebif is a tough sell in this day and age. If Clad gets approved, things could be better, however the expansion seems very extreme considering how niche this drug could possibly be. Would prefer if they left territories alone and just added Clad to our bag. A 33% increase in sales reps for a drug that will likely be used primarily in MS Centers may not make it easy to meet goals. Tons of turnover in the company (upper management and throughout). As with any job, your manager can make your life good, or miserable. Overall, it's been a good company, but the boat has been rocking for several years. And the company seems to be focusing primarily on Oncology, though not sure how well that's working out for them. Rebif still keeps the lights on.

 

[anonymous]

Would love to know this answer??

7% and sinking with H2H data from Ocrevus harder and harder to sell against. Millian is a putz